Journal
BIOCHEMICAL PHARMACOLOGY
Volume 90, Issue 4, Pages 414-424Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2014.06.013
Keywords
Nonalcoholic fatty liver disease (NAFLD); Liver X receptor alpha (LXR alpha); Sterol-response element binding protein 1c (SREBP1c); Receptor interacting protein 140 (RIP140); Reverse cholesterol transport
Categories
Funding
- Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A121185]
Ask authors/readers for more resources
Collaborative regulation of liver X receptor (LXR) and sterol regulatory element binding protein (SREBP)1 are main determinants in hepatic steatosis, as shown in both animal models and human patients. Recent studies indicate that selective intervention of overly functional LXR alpha in the liver shows promise in treatment of fatty liver disease. In the present study, we evaluated the effects of meso-dihydroguaiaretic acid (MDGA) on LXR alpha activation and its ability to attenuate fatty liver in mice. MDGA inhibited activation of the LXR alpha ligand-binding domain by competitively binding to the pocket for agonist T0901317 and decreased the luciferase activity in LXRE-tk-Luc-transfected cells. MDGA significantly attenuated hepatic neutral lipid accumulation in T0901317- and high fat diet (HFD)-induced fatty liver. The effect of MDGA was so potent that treatment with 1 mg/kg for 2 weeks completely reversed the lipid accumulation induced by HFD feeding. MDGA reduced the expression of LXR alpha co-activator protein RIP140 and LXR alpha target gene products associated with lipogenesis in HFD-fed mice. These results demonstrate that MDGA has the potential to attenuate nonalcoholic steatosis mediated by selective inhibition of LXRa in the liver in mice. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available